Pharmaceuticals

Alpha Mannosidosis Market Insights Highlighting Opportunities Supporting Growth To 2030

April 28, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Growth In Market Value Is Expected For The Alpha Mannosidosis Market Between 2026 And 2030?

The alpha mannosidosis market has experienced rapid expansion in recent years. Its size is projected to increase from $17.87 billion in 2025 to $21 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 17.5%. The historical growth in this market can be attributed to factors such as limited diagnostic infrastructure, low disease awareness, a reliance on conventional therapies, fragmented treatment guidelines, and restricted R&D funding.

The alpha mannosidosis market is projected to experience substantial expansion over the upcoming years, with its valuation expected to reach $39.41 billion by 2030, growing at a compound annual growth rate (CAGR) of 17.0%. This anticipated growth during the forecast period is driven by factors such as increased investment in gene therapies, the rising adoption of enzyme replacement therapies, an expanding healthcare infrastructure, advancements in diagnostic technologies, and regulatory incentives aimed at rare diseases. Prominent trends observed throughout this period include the implementation of early genetic screening programs, the development of orphan drugs, the evolution of personalized enzyme replacement therapy, an increase in rare disease clinics, and collaborative research initiatives.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=4093&type=smp

Which Key Factors Are Driving The Alpha Mannosidosis Market Growth?

Increased demand for precision medicine is anticipated to boost the alpha mannosidosis market’s expansion. This involves a customized healthcare strategy, accounting for unique patient attributes such as genetic makeup, environmental factors, and lifestyle choices to refine treatment and prevention methods. Its proliferation is fueled by progress in genomic technologies and data analytics, facilitating a more precise identification of genetic variations and their health consequences. Moreover, the growing need for individualized therapy options, coupled with a greater understanding of the drawbacks of universal treatments, has spurred enthusiasm for customized healthcare solutions. For alpha mannosidosis, precision medicine aids in creating targeted therapies specifically designed for the genetic mutations and patient characteristics linked to this rare condition. An example highlighting this trend is the report from the Personalized Medicine Coalition (PMC), a US-based nonprofit, which stated in February 2024 that the FDA cleared 16 new personalized treatments for rare diseases in 2023, a significant jump from only six approvals in 2022. Consequently, the escalating demand for precision medicine is acting as a primary catalyst for the alpha mannosidosis market’s expansion.

What Are The Different Segment Types In The Alpha Mannosidosis Market Segment Breakdown?

The alpha mannosidosis market covered in this report is segmented –

1) By Therapy Type: Bone Marrow Transplant (BMT), Enzyme Replacement Therapy (ERT), Other Therapies

2) By Indication: Type I, Type II, Type III

3) By End-User: Hospitals, Speciality Clinics

Subsegments:

1) By Bone Marrow Transplant (BMT): Autologous BMT, Allogeneic BMT

2) By Enzyme Replacement Therapy (ERT): Recombinant Enzymes, Long-acting Enzyme Formulations

3) By Other Therapies: Symptomatic Treatments, Gene Therapy, Supportive Care

Which Trends Are Contributing To Changes In The Alpha Mannosidosis Market?

Companies operating within the alpha mannosidosis market are concentrating on developing enzyme replacement therapy for the uncommon condition of alpha-mannosidosis. This therapy works by introducing exogenous alpha-mannosidase, which aids in reducing the build-up of mannose-rich oligosaccharides in various tissues and organs. Such accumulation is a characteristic sign of alpha-mannosidosis and contributes to its pathological outcomes. For instance, in February 2023, Chiesi Global Rare Diseases, a US-based pharmaceutical company, introduced Lamzede (velmanase alfa). This was the first enzyme replacement therapy sanctioned in the United States for addressing alpha-mannosidosis, a rare genetic disorder marked by a deficiency of the alpha-mannosidase enzyme in the body, and its symptoms excluding those of the central nervous system. Lamzede restores normal cellular activity in patients by mimicking the action of the human body’s alpha-mannosidase enzyme. Patients receive a 10 mg injection of Lamzede on a weekly basis.

Who Are The Well-Known Companies In The Alpha Mannosidosis Market?

Major companies operating in the alpha mannosidosis market are Chiesi Farmaceutici S.p.A., Cipla, Daiichi Sankyo Company, Ultragenyx Pharmaceutical Inc, Mitsubishi Tanabe Pharma, Zymenex A/S, Albumedix Ltd, Freeline Therapeutics, Avectas, DiNAQOR AG, Vivet Therapeutics, Herantis Pharma Plc, PTC Therapeutics, Biocad, Sanofi, Orchard Therapeutics, Shire Pharmaceuticals, Amicus Therapeutics, BioMarin Pharmaceutical Inc, Genzyme

Get The Full Alpha Mannosidosis Market Report:

https://www.thebusinessresearchcompany.com/report/alphas-mannosidosis-global-market-report

Which Geographic Region Dominates The Alpha Mannosidosis Market?

North America was the largest region in the alpha mannosidosis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the alpha mannosidosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Alpha Mannosidosis Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/alphas-mannosidosis-global-market-report

Browse Through More Reports Similar to the Global Alpha Mannosidosis Market 2026, By The Business Research Company

Alpha Mannosidosis Market 2026

https://www.thebusinessresearchcompany.com/report/alpha-mannosidosis-global-market

Mannan Oligosaccharide Market Report 2026

https://www.thebusinessresearchcompany.com/report/mannan-oligosaccharide-global-market-report

Immunoassay Market Report 2026

https://www.thebusinessresearchcompany.com/report/immunoassay-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795